DK3065764T6 - Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling - Google Patents

Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling Download PDF

Info

Publication number
DK3065764T6
DK3065764T6 DK14795569.4T DK14795569T DK3065764T6 DK 3065764 T6 DK3065764 T6 DK 3065764T6 DK 14795569 T DK14795569 T DK 14795569T DK 3065764 T6 DK3065764 T6 DK 3065764T6
Authority
DK
Denmark
Prior art keywords
cck
mini
treatment
receptor positive
positive tumor
Prior art date
Application number
DK14795569.4T
Other languages
English (en)
Other versions
DK3065764T3 (da
Inventor
Martin Behe
Roger Schibli
Original Assignee
Scherrer Inst Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherrer Inst Paul filed Critical Scherrer Inst Paul
Application granted granted Critical
Publication of DK3065764T3 publication Critical patent/DK3065764T3/da
Publication of DK3065764T6 publication Critical patent/DK3065764T6/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57572Gastrin releasing peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2207Gastrins; Cholecystokinins [CCK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13Labelling of peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/595Gastrins; Cholecystokinins [CCK]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
DK14795569.4T 2013-11-06 2014-10-23 Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling DK3065764T6 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130191807 EP2870972A1 (en) 2013-11-06 2013-11-06 Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment
PCT/EP2014/072697 WO2015067473A1 (en) 2013-11-06 2014-10-23 Mini-gastrin analogue, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment

Publications (2)

Publication Number Publication Date
DK3065764T3 DK3065764T3 (da) 2018-03-12
DK3065764T6 true DK3065764T6 (da) 2023-11-06

Family

ID=49518847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14795569.4T DK3065764T6 (da) 2013-11-06 2014-10-23 Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling

Country Status (18)

Country Link
US (3) US10130724B2 (da)
EP (2) EP2870972A1 (da)
JP (3) JP2017501116A (da)
KR (2) KR20160070160A (da)
CN (1) CN105705159B (da)
CY (1) CY1120117T1 (da)
DK (1) DK3065764T6 (da)
ES (1) ES2670582T3 (da)
HR (1) HRP20180631T1 (da)
HU (1) HUE036943T2 (da)
LT (1) LT3065764T (da)
NO (1) NO3065764T3 (da)
PL (1) PL3065764T6 (da)
PT (1) PT3065764T (da)
RS (1) RS57137B1 (da)
SI (1) SI3065764T1 (da)
TR (1) TR201802723T4 (da)
WO (1) WO2015067473A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870972A1 (en) * 2013-11-06 2015-05-13 Paul Scherrer Institut Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment
EP3509617A4 (en) * 2016-09-09 2020-05-13 On Target Laboratories, LLC NIR IMAGING AND USE OF THE CHOLECYSTOKININ-2 RECEPTOR
EP3412303A1 (en) 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
EP3459559A1 (en) * 2017-09-21 2019-03-27 Paul Scherrer Institut Minigastrin derivates, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment
CN112584843A (zh) 2018-06-22 2021-03-30 顺天生化股份有限公司 用于诱发感染性免疫耐受的组合物
BR112020025504A2 (pt) 2018-06-22 2021-03-16 Junten Bio Co., Ltd. Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido
TWI832869B (zh) 2018-06-22 2024-02-21 日商順天生化股份有限公司 使用具有複合狀態之細胞混合物之誘導免疫耐受之抗體、及被誘導之淋巴球、以及使用被誘導之淋巴球之細胞治療劑及治療法
EP3868394A1 (en) * 2020-02-20 2021-08-25 Paul Scherrer Institut Mono- and multi-triazolominigastrins for targeting of cck2r-positive neoplasms
WO2021186060A1 (en) 2020-03-20 2021-09-23 Debiopharm International S.A. Radiolabeled gastrin analogue for use in a method of treating and/or imaging cckb receptor positive diseases, in particular pulmonary and extrapulmonary small-cell carcinoma
KR20230028516A (ko) 2020-07-31 2023-02-28 폴 슈레 앙스띠뛰 특히, cckb 수용체 양성 암 또는 종양의 치료 및/또는 진단에서 사용하기 위한, 라파로그 및 방사성표지된 가스트린 유사체를 포함하는 조성물
KR20230028515A (ko) 2020-07-31 2023-02-28 폴 슈레 앙스띠뛰 알파 방사성표지된 가스트린 유사체 및 cckb 수용체 양성 질환의 치료 방법에서의 그의 용도
US20230270893A1 (en) 2020-07-31 2023-08-31 Debiopharm International S.A. Gallium-labeled gastrin analogue and use in a method of imaging cckb-receptor-positive tumors or cancers
KR20230152698A (ko) 2021-02-02 2023-11-03 메디지니쉐 유니버시타트 인스브루크 진단 및 요법을 위한 개선된 콜레시스토키닌-2 수용체(cck2r) 표적화
KR20240052015A (ko) 2021-09-28 2024-04-22 폴 슈레 앙스띠뛰 Cck2-r을 표적화하는 화합물을 사용한 치료 및/또는 영상화에 대한 암으로 진단된 환자의 반응을 예측하는 방법, 및 암을 선택적으로 치료 및/또는 영상화하는 방법에서 사용하기 위한 화합물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650787A (en) * 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
EP2870972A1 (en) * 2013-11-06 2015-05-13 Paul Scherrer Institut Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment

Also Published As

Publication number Publication date
US20210145990A1 (en) 2021-05-20
KR20180094125A (ko) 2018-08-22
KR20160070160A (ko) 2016-06-17
CY1120117T1 (el) 2018-12-12
EP3065764A1 (en) 2016-09-14
US10953114B2 (en) 2021-03-23
KR102039930B1 (ko) 2019-11-05
TR201802723T4 (tr) 2018-03-21
HUE036943T2 (hu) 2018-08-28
CN105705159A (zh) 2016-06-22
US20160256580A1 (en) 2016-09-08
DK3065764T3 (da) 2018-03-12
US20190240360A1 (en) 2019-08-08
JP2018118996A (ja) 2018-08-02
SI3065764T1 (en) 2018-05-31
US11623014B2 (en) 2023-04-11
LT3065764T (lt) 2018-05-10
PL3065764T6 (pl) 2024-01-15
PT3065764T (pt) 2018-03-28
NO3065764T3 (da) 2018-07-21
ES2670582T3 (es) 2018-05-31
PL3065764T3 (pl) 2018-07-31
JP2017501116A (ja) 2017-01-12
EP2870972A1 (en) 2015-05-13
HRP20180631T1 (hr) 2018-06-01
JP6568618B2 (ja) 2019-08-28
US10130724B2 (en) 2018-11-20
WO2015067473A1 (en) 2015-05-14
EP3065764B3 (en) 2023-10-11
EP3065764B1 (en) 2018-02-21
JP2019218364A (ja) 2019-12-26
CN105705159B (zh) 2021-02-12
RS57137B1 (sr) 2018-07-31
JP6763069B2 (ja) 2020-09-30

Similar Documents

Publication Publication Date Title
DK3065764T6 (da) Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling
DK2986304T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
HK1222530A1 (zh) 用於皮膚處理的微閉合及相關方法
DK3019483T3 (da) Terapeutiske aktive forbindelser og fremgangsmåder til deres anvendelse
DK3027208T3 (da) Cancerdiagnose og -terapi, der involverer cancerstamceller
HK1222778A1 (zh) 醫用裝置及使用該醫用裝置的方法
BR112015007494A2 (pt) aparelho para tratamento dentário.
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
DK2838900T3 (da) Forbindelser og fremgangsmåder til antiviral behandling
HUE063194T2 (hu) FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
DK3311845T3 (da) Terapeutiske polymernanopartikler og fremgangsmåder til fremstilling og anvendelse heraf
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
BR302013006822S1 (pt) Configuração aplicada em curativo médico.
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK2764881T3 (da) System til medicinsk behandling
DK3122332T3 (da) Opløselige mikronåle til hudbehandling
DK2989200T3 (da) Fremgangsmåder til at opnå retinaprogenitorer, retinapigmenterede epitelceller og neurale retinaceller
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK3104838T3 (da) Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
EP3015077A4 (en) TREATMENT INSTRUMENT FOR ENDOSCOPE AND ENDOSCOPY SYSTEM
DK2816947T3 (da) Endoskopisk anordning, særlig til medicinsk brug
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling
DK2978846T3 (da) Modificeret tgf-beta-oligonukleotid til anvendelse i en fremgangsmåde til forebyggelse og/eller behandling af en oftalmisk sygdom
DK3083678T3 (da) Midler og fremgangsmåder til at modvirke myeloproliferative eller lymfoproliferative forstyrrelser
EP2949274A4 (en) HEART TREATMENT DEVICE